AcromegalyACROMORFONCT05964712
Effects of Therapies in the Acromegaly Disease: Acral Morpho-functional Study
An observational study of Acromegaly, run by Istituto Auxologico Italiano at 1 site in Italy.
Trial summary
Acromegaly is a rare chronic disease due to excessive secretion of growth hormone (GH) and insulin-like growth factor-I (IGF-I), caused in over 98% of cases by GH-secreting pituitary adenoma. Prolonged exposure to GH/IGF-I excess is the cause of increased mortality and morbidity in these patients. Read more about this study
- Who is it for?
- Ages 18 to 90 years
- Conditions the study is for
- Acromegaly
- What is being tested?
- Medical surgery therapy
- Type of treatment
- Surgery or procedure
- How many people
- 30 participants
- Where
- 1 siteItaly
- Study dates
- 18 Jun 2019to 31 Dec 2025
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 90 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Group #1: De novo patients with acromegaly, diagnosed according to Endocrine Society guidelines, aged equal or above 18 years old; Group #2: Acromegalic patients with different disease status (active disease despite ongoing therapies, controlled disease under medical therapy, and disease remission), aged equal or above 18 years old
Who may be able to join
- De novo patients with acromegaly (group # 1), diagnosed according to Endocrine Society guidelines,
- Age equal to18 years or older
- Acromegalic patients with different disease status (group #2)
- Age equal to18 years or older
Who cannot join
- Cardiorespiratory, neurological or musculoskeletal disorder
- Previous orthopaedic surgery
- Previous lower limbs traumatic injuries
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Italy1 site, 1 recruiting
- Recruiting
Istituto Auxologico Italiano IRCCS San Luca
Milan, 20149
Giovanni Vitale, g.vitale@auxologico.it
About this study
Acromegaly is a rare chronic disease due to excessive secretion of growth hormone (GH) and insulin-like growth factor-I (IGF-I), caused in over 98% of cases by GH-secreting pituitary adenoma. Prolonged exposure to GH/IGF-I excess is the cause of increased mortality and morbidity in these patients. Arthropathy occurs in about 75% of acromegalic patients. Any joint may be affected, with the development of osteoarthritis, arthralgia, and an increase in fracture risk.
The aims of the present project are to evaluate the dimensions of hands and feet with the 3D scanner method and to perform a quantitative analysis of movement through Gait Analysis technique in de novo patients with acromegaly (group # 1) and in patients with different disease status (group #2).
Read the detailed description
This is an observational, prospective study that aims to evaluate the effect of acromegalic disease and medical/surgical therapy on acral morpho-functional alterations.
To outline the morphological characteristics of the extremities (hands and feet), a three-dimensional laser scanning system will be used able to measure the geometrical and volumetric characteristics of the hands and feet of these subjects. The three-dimensional scanning system that will be used is the portable FastScan system (marketed by Rodin), previously used for the volumetric evaluation of the lower and upper limbs of subjects suffering from lymphedema and lipedema. The processing of the image and the parameters will be carried out through two softwares: Rodin4DScan, which carries out the reconstruction of the shape after the scan, and Rodin4D, which allows the construction of the final shape and allows the processing of the various parameters to the morphology of the extremity.
The following tests will be used to characterize posture and balance control during walking:
- maintenance of the bipedal indifferent orthostatic posture, with open and closed eyes;
- walking on level ground, barefoot, at natural speed (10 m walking test)
The instrumentation (BTS GAITLAB) that will be used consists of:
- 8-camera stereophotogrammetric system (SMART DX, BTS-Bioengineering, IT);
- two dynamometric platforms (AMTI, USA);
- a baropodometric platform (P-WALK; BTS-Bioengineering, IT).
The variables analyzed will be divided according to the administered tests:
- maintenance of the orthostatic posture: anteroposterior and mediolateral excursion of the center of pressure, speed of displacement of the center of pressure, length of postural ball and distribution of plantar pressures;
- gait: spatio-temporal parameters, kinematics of trunk and joints of lower limbs, ground reaction forces, moments and joint powers.
A functional evaluation of the foot will be also performed positioning the patient prone/supine on the bed and measuring several joint angles.
The measurement will be supported by a video from which images can be subsequently processed to trace and obtain the joint angles.
For the functional evaluation of the hand, the patient will be evaluated with the following outcome measures:
- Algo-functional index of the hand according to Dreiser, which analyzes the ability to execute some gestures of daily life;
- Duruöz index, questionnaire for assessing functional impairment of hand.
- Conditions
- Acromegaly
- Being tested
- Medical surgery therapy
- Medical subject headings
- Acromegaly
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Medical surgery therapyProcedure or surgery
De novo patients with acromegaly will undergo medical/surgical therapy of this disease, according to the guidelines of the Endocrine Society. In this population (group #1) morpho-functional examinations together with the evaluation of the stage of the disease, with serum dosage of GH and IGF-1, will be performed at baseline and at months 3, 6 and 12 after initiating the treatment.
| Study group | Role | What they receive |
|---|---|---|
| Population # 1 | De novo patients with acromegaly, diagnosed according to Endocrine Society guidelines, aged equal or above 18 years old Receives: Procedure: Medical surgery therapy | |
| Population # 2 | Acromegalic patients with different disease status (active disease despite ongoing therapies, controlled disease under medical therapy, and disease remission), aged equal or above 18 years old |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in serum concentration of GH and IGF1
Serum concentration of GH and IGF1
Measured: At baseline in population #1 and # 2 and at 3, 6, 12 months after intervention in population #1
Change in postural
The postural evaluation was performed for 60 seconds while the participants were standing on a baropodometric platform (P-Walk, BTSBioengineering, Italy). They were instructed to maintain an upright position, with their eyes focused on a 6 cm black circle placed at their individual eye level, at a distance of 1.5 meters. Subsequently, they were asked to repeat the same task with their eyes closed. To avoid any learning or fatigue effects, two evaluations were acquired with open eyes and two with closed eyes, and between each trial, the subjects were allowed to rest and sit for 2 minutes, maintaining the foot position during the tests.
Postural parameters were calculated using dedicated software (G-Studio, BTS, Italy). The relative range of the center of pressure track length is essentially the difference between the maximum and minimum CoP position in the anterior-posterior and medial-lateral (ML) directions during the maintenance of the upright posture.
Measured: At baseline in population #1 and # 2 and at 3, 6, 12 months after intervention in population #1
Gait analysis
All participants were evaluated with 3D-Gait Analysis using an optoelectronic system composed of eight cameras (SMARTDX, BTSBioengineering, Italy) set at 100 Hz, and two force platforms (AMTI, USA). To evaluate the kinematics of each body segment, passive markers were positioned on the participants' body, as described by Davis III et al., and the underlying skeletal model was scaled on behalf of anthropometric data (height, weight, tibial length, distance between the femoral condyles or diameter of the knee, distance between the malleoli or diameter of the ankle, distance between the anterior iliac spines and thickness of the pelvis).
After placing the markers, the participants were asked to walk barefoot at self-selected speed along a walkway where the force platforms were embedded. Kinematic and kinetic data were collected for each individual from at least five trials to guarantee the reproducibility of the results.
Measured: At baseline in population #1 and # 2 and at 3, 6, 12 months after intervention in population #1
Change in function of the foot - angle ankle joint
The functional evaluation of the foot involves positioning the patient prone/supine on the bed and assessing the ankle joint
Measured: At baseline in population #1 and # 2 and at 3, 6, 12 months after intervention in population #1
Change in function of the foot - angle subtalar joint
The functional evaluation of the foot involves positioning the patient prone/supine on the bed and assessing the subtalar joint
Measured: At baseline in population #1 and # 2 and at 3, 6, 12 months after intervention in population #1
Change in function of the foot - angle metatarsophalangeal joint of the big toe
The functional evaluation of the foot involves positioning the patient prone/supine on the bed and assessing the metatarsophalangeal joint of the big toe
Measured: At baseline in population #1 and # 2 and at 3, 6, 12 months after intervention in population #1
Change in Function of the hand - Dreiser functional index
Algo-functional index of the hand according to Dreiser functional index
Measured: At baseline in population #1 and # 2 and at 3, 6, 12 months after intervention in population #1
Change in Function of the hand - Duruöz hand index
Algo-functional index of the hand according to Duruöz hand index
Measured: At baseline in population #1 and # 2 and at 3, 6, 12 months after intervention in population #1
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted28 Jul 2023
- Study start18 Jun 2019
- Primary completion31 Dec 2025 (estimated)
- Study completion31 Dec 2025 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for AcromegalyStudies of the same condition, open and under way.
- More trials run by Istituto Auxologico ItalianoThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 30 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Istituto Auxologico Italiano
- Sponsor type
- University, hospital or other
- Collaborators
- Politecnico di Milano
- Responsible party
- Sponsor
- Investigators
- Giovanni Vitale, Principal investigator, Istituto Auxologico Italiano IRCCS
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05964712
- Sponsor's protocol ID
- 40C901
- Acronym
- ACROMORFO
- Status last verified
- Aug 2025
- First submitted
- 2 Mar 2023
- Last updated
- 3 Aug 2025
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 3 Aug 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Effects of Therapies in the Acromegaly Disease: Acral Morpho-functional Study
- ClinicalTrials.gov ID
- NCT05964712
- Acronym / sponsor ID
- ACROMORFO / 40C901
- Conditions
- Acromegaly
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 30 participants (estimated)
- Lead sponsor
- Istituto Auxologico ItalianoUniversity, hospital or other
- Collaborators
- Politecnico di Milano
- Study start
- 18 Jun 2019 (actual)
- Primary completion
- 31 Dec 2025 (estimated)
- Study completion
- 31 Dec 2025 (estimated)
- First posted
- 28 Jul 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Acromegaly is a rare chronic disease due to excessive secretion of growth hormone (GH) and insulin-like growth factor-I (IGF-I), caused in over 98% of cases by GH-secreting pituitary adenoma. Prolonged exposure to GH/IGF-I excess is the cause of increased mortality and morbidity in these patients. Arthropathy occurs in about 75% of acromegalic patients. Any joint may be affected, with the development of osteoarthritis, arthralgia, and an increase in fracture risk.
The aims of the present project are to evaluate the dimensions of hands and feet with the 3D scanner method and to perform a quantitative analysis of movement through Gait Analysis technique in de novo patients with acromegaly (group # 1) and in patients with different disease status (group #2).
Detailed description
This is an observational, prospective study that aims to evaluate the effect of acromegalic disease and medical/surgical therapy on acral morpho-functional alterations.
To outline the morphological characteristics of the extremities (hands and feet), a three-dimensional laser scanning system will be used able to measure the geometrical and volumetric characteristics of the hands and feet of these subjects. The three-dimensional scanning system that will be used is the portable FastScan system (marketed by Rodin), previously used for the volumetric evaluation of the lower and upper limbs of subjects suffering from lymphedema and lipedema. The processing of the image and the parameters will be carried out through two softwares: Rodin4DScan, which carries out the reconstruction of the shape after the scan, and Rodin4D, which allows the construction of the final shape and allows the processing of the various parameters to the morphology of the extremity.
The following tests will be used to characterize posture and balance control during walking:
- maintenance of the bipedal indifferent orthostatic posture, with open and closed eyes;
- walking on level ground, barefoot, at natural speed (10 m walking test)
The instrumentation (BTS GAITLAB) that will be used consists of:
- 8-camera stereophotogrammetric system (SMART DX, BTS-Bioengineering, IT);
- two dynamometric platforms (AMTI, USA);
- a baropodometric platform (P-WALK; BTS-Bioengineering, IT).
The variables analyzed will be divided according to the administered tests:
- maintenance of the orthostatic posture: anteroposterior and mediolateral excursion of the center of pressure, speed of displacement of the center of pressure, length of postural ball and distribution of plantar pressures;
- gait: spatio-temporal parameters, kinematics of trunk and joints of lower limbs, ground reaction forces, moments and joint powers.
A functional evaluation of the foot will be also performed positioning the patient prone/supine on the bed and measuring several joint angles.
The measurement will be supported by a video from which images can be subsequently processed to trace and obtain the joint angles.
For the functional evaluation of the hand, the patient will be evaluated with the following outcome measures:
- Algo-functional index of the hand according to Dreiser, which analyzes the ability to execute some gestures of daily life;
- Duruöz index, questionnaire for assessing functional impairment of hand.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Population # 1 | – | Procedure: Medical surgery therapyDe novo patients with acromegaly, diagnosed according to Endocrine Society guidelines, aged equal or above 18 years old |
| Population # 2 | – | –Acromegalic patients with different disease status (active disease despite ongoing therapies, controlled disease under medical therapy, and disease remission), aged equal or above 18 years old |
Who may qualify
- Ages
- 18 to 90 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Group #1: De novo patients with acromegaly, diagnosed according to Endocrine Society guidelines, aged equal or above 18 years old; Group #2: Acromegalic patients with different disease status (active disease despite ongoing therapies, controlled disease under medical therapy, and disease remission), aged equal or above 18 years old
Key inclusion criteria (4 listed)
- De novo patients with acromegaly (group # 1), diagnosed according to Endocrine Society guidelines,
- Age equal to18 years or older
- Acromegalic patients with different disease status (group #2)
- Age equal to18 years or older
Key exclusion criteria (3 listed)
- Cardiorespiratory, neurological or musculoskeletal disorder
- Previous orthopaedic surgery
- Previous lower limbs traumatic injuries
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Medical surgery therapyDe novo patients with acromegaly will undergo medical/surgical therapy of this disease, according to the guidelines of the Endocrine Society. In this population (group #1) morpho-functional examinations together with the evaluation of the stage of the disease, with serum dosage of GH and IGF-1, will be performed at baseline and at months 3, 6 and 12 after initiating the treatment. | Procedure or surgery | Population # 1 |
Primary outcome
Change in serum concentration of GH and IGF1
Time frame: At baseline in population #1 and # 2 and at 3, 6, 12 months after intervention in population #1
Serum concentration of GH and IGF1
Change in postural
Time frame: At baseline in population #1 and # 2 and at 3, 6, 12 months after intervention in population #1
The postural evaluation was performed for 60 seconds while the participants were standing on a baropodometric platform (P-Walk, BTSBioengineering, Italy). They were instructed to maintain an upright position, with their eyes focused on a 6 cm black circle placed at their individual eye level, at a distance of 1.5 meters. Subsequently, they were asked to repeat the same task with their eyes closed. To avoid any learning or fatigue effects, two evaluations were acquired with open eyes and two with closed eyes, and between each trial, the subjects were allowed to rest and sit for 2 minutes, maintaining the foot position during the tests. Postural parameters were calculated using dedicated software (G-Studio, BTS, Italy). The relative range of the center of pressure track length is essentially the difference between the maximum and minimum CoP position in the anterior-posterior and medial-lateral (ML) directions during the maintenance of the upright posture.
Gait analysis
Time frame: At baseline in population #1 and # 2 and at 3, 6, 12 months after intervention in population #1
All participants were evaluated with 3D-Gait Analysis using an optoelectronic system composed of eight cameras (SMARTDX, BTSBioengineering, Italy) set at 100 Hz, and two force platforms (AMTI, USA). To evaluate the kinematics of each body segment, passive markers were positioned on the participants' body, as described by Davis III et al., and the underlying skeletal model was scaled on behalf of anthropometric data (height, weight, tibial length, distance between the femoral condyles or diameter of the knee, distance between the malleoli or diameter of the ankle, distance between the anterior iliac spines and thickness of the pelvis). After placing the markers, the participants were asked to walk barefoot at self-selected speed along a walkway where the force platforms were embedded. Kinematic and kinetic data were collected for each individual from at least five trials to guarantee the reproducibility of the results.
Change in function of the foot - angle ankle joint
Time frame: At baseline in population #1 and # 2 and at 3, 6, 12 months after intervention in population #1
The functional evaluation of the foot involves positioning the patient prone/supine on the bed and assessing the ankle joint
Change in function of the foot - angle subtalar joint
Time frame: At baseline in population #1 and # 2 and at 3, 6, 12 months after intervention in population #1
The functional evaluation of the foot involves positioning the patient prone/supine on the bed and assessing the subtalar joint
Change in function of the foot - angle metatarsophalangeal joint of the big toe
Time frame: At baseline in population #1 and # 2 and at 3, 6, 12 months after intervention in population #1
The functional evaluation of the foot involves positioning the patient prone/supine on the bed and assessing the metatarsophalangeal joint of the big toe
Change in Function of the hand - Dreiser functional index
Time frame: At baseline in population #1 and # 2 and at 3, 6, 12 months after intervention in population #1
Algo-functional index of the hand according to Dreiser functional index
Change in Function of the hand - Duruöz hand index
Time frame: At baseline in population #1 and # 2 and at 3, 6, 12 months after intervention in population #1
Algo-functional index of the hand according to Duruöz hand index
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 3 Aug 2025.
Related trials for Acromegaly
RecruitingPhase 1
A Phase 1 Clinical Trial of NTQ6179 Tablets in Healthy Volunteers
Acromegaly
RecruitingObservational study
An Observational Study of Octreotide Subcutaneous Depot in Patients With Acromegaly
Acromegaly
RecruitingPhase 3
A Study to Assess the Efficacy and Safety of Debio 4126 in Participants With Acromegaly Previously Treated With Somatostatin Analogs
Acromegaly
RecruitingObservational study
An Investigation of Pituitary Tumors and Related Hypothalmic Disorders
Panhypopituitarism, Gigantism/Acromegaly
Recruiting
Managing Pasireotide-associated Hyperglycaemia in Acromegaly With Ketogenic Diet
Acromegaly Due to Pituitary Adenoma, Hyperglycemia
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Giovanni Vitale principal investigator
Istituto Auxologico Italiano IRCCS
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Acromegaly, run by Istituto Auxologico Italiano at 1 site in Italy.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 3 Aug 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Italy. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Sara Farina, Doctor (+393386822298, sara.farina@unimi.it), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in serum concentration of GH and IGF1 (time frame: At baseline in population #1 and # 2 and at 3, 6, 12 months after intervention in population #1). The study lists 8 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 3 Aug 2025.